Merck KGaA/€MRK
06:30
10:10
13:45
17:25
21:00
1D1W1MYTD1Y5YMAX
About Merck KGaA
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Ticker
€MRK
Sector
Primary listing
XETRA
Employees
59,077
Headquarters
Website
Merck KGaA Metrics
BasicAdvanced
€48B
18.43
€6.00
0.72
€2.20
1.99%
Price and volume
Market cap
€48B
Beta
0.72
52-week high
€137.45
52-week low
€100.65
Average daily volume
14K
Dividend rate
€2.20
Financial strength
Current ratio
1.463
Quick ratio
0.897
Long term debt to equity
37.439
Total debt to equity
41.759
Dividend payout ratio (TTM)
39.84%
Interest coverage (TTM)
12.06%
Profitability
EBITDA (TTM)
5,700
Gross margin (TTM)
58.90%
Net profit margin (TTM)
12.36%
Operating margin (TTM)
18.62%
Effective tax rate (TTM)
20.95%
Revenue per employee (TTM)
€360,000
Management effectiveness
Return on assets (TTM)
4.76%
Return on equity (TTM)
8.92%
Valuation
Price to earnings (TTM)
18.434
Price to revenue (TTM)
2.278
Price to book
1.69
Price to tangible book (TTM)
16.1
Price to free cash flow (TTM)
22.413
Free cash flow yield (TTM)
4.46%
Free cash flow per share (TTM)
4.934
Dividend yield (TTM)
1.99%
Forward dividend yield
1.99%
Growth
Revenue change (TTM)
-0.26%
Earnings per share change (TTM)
-6.09%
3-year revenue growth (CAGR)
-1.72%
10-year revenue growth (CAGR)
5.09%
3-year earnings per share growth (CAGR)
-7.79%
10-year earnings per share growth (CAGR)
8.89%
10-year dividend per share growth (CAGR)
7.68%
What the Analysts think about Merck KGaA
Analyst ratings (Buy, Hold, Sell) for Merck KGaA stock.
Merck KGaA Financial Performance
Revenues and expenses
Merck KGaA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Merck KGaA stock?
Merck KGaA (MRK) has a market cap of €48B as of March 11, 2026.
What is the P/E ratio for Merck KGaA stock?
The price to earnings (P/E) ratio for Merck KGaA (MRK) stock is 18.43 as of March 11, 2026.
Does Merck KGaA stock pay dividends?
Yes, the Merck KGaA (MRK) stock pays dividends to shareholders. As of March 11, 2026, the dividend rate is €2.2 and the yield is 1.99%. Merck KGaA has a payout ratio of 39.84% on a trailing twelve-month basis.
When is the next Merck KGaA dividend payment date?
The next Merck KGaA (MRK) dividend payment is scheduled for April 29, 2026.
What is the beta indicator for Merck KGaA?
Merck KGaA (MRK) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.